Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains

Neurobiology of Aging

Volumn 36, Issue 9, 2015, Pages 2649-2659

  Liu, Guangwei ^a,b   Chen, Min ^a,c   Mi, Na ^a,b   Yang, Weiwei ^a,b   Li, Xin ^a,b   Wang, Peng ^a,b   Yin, Na ^a,b   Li, Yaohua ^a,b   Yue, Feng ^a,b   Chan, Piu ^a,b,c   Yu, Shun ^a,b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c Beijing Key Laboratory for Parkinson's Disease   (China)

Author keywords

Aging; Cynomolgus monkey; Dementia with lewy bodies; Glucocerebrosidase; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; OLIGOMER; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE; PEPTIDE; PHOSPHOPROTEIN PHOSPHATASE 2;

ADOLESCENT; AGING; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN REGION; BRAIN TISSUE; CELL FRACTIONATION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME DEFECT; ENZYME INHIBITION; HAPLORHINI; HIPPOCAMPUS; IN VITRO STUDY; LYSOSOME; NERVE CELL; NERVE DEGENERATION; NEWBORN; NONHUMAN; OCCIPITAL CORTEX; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; ANIMAL; BRAIN; CELL CULTURE; CHEMISTRY; CYTOLOGY; CYTOSOL; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MACACA FASCICULARIS; METABOLISM; MITOCHONDRION; PHOSPHORYLATION; PHYSIOLOGY; ULTRASTRUCTURE; WISTAR RAT;

AGING; ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELLS, CULTURED; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLUCOSYLCERAMIDASE; MACACA FASCICULARIS; MITOCHONDRIA; NEURONS; PEPTIDES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; RATS; RATS, WISTAR;

EID: 84940467091     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.06.004     Document Type: Article

References (65)

1. Alim M.A., Hossain M.S., Arima K., Takeda K., Izumiyama Y., Nakamura M., Kaji H., Shinoda T., Hisanaga S., Uéda K. Tubulin seeds alpha-synuclein fibril formation. J.Biol. Chem. 2002, 277:2112-2117.
2. Arawaka S., Wada M., Goto S., Karube H., Sakamoto M., Ren C.H., Koyama S., Nagasawa H., Kimura H., Kawanami T., Kurita K., Tajima K., Daimon M., Baba M., Kido T., Saino S., Goto K., Asao H., Kitanaka C., Takashita E., Hongo S., Nakamura T., Kayama T., Suzuki Y., Kobayashi K., Katagiri T., Kurokawa K., Kurimura M., Toyoshima I., Niizato K., Tsuchiya K., Iwatsubo T., Muramatsu M., Matsumine H., Kato T. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J.Neurosci. 2006, 26:9227-9238.
3. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
4. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. Chalfant C.E., Kishikawa K., Mumby M.C., Kamibayashi C., Bielawska A., Hannun Y.A. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J.Biol. Chem. 1999, 274:20313-20317.
6. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destée A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
7. Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neuronsand results in increased mitophagy invivo. Neurosci. Lett. 2010, 486:235-239.
8. Choi B.K., Choi M.G., Kim J.Y., Yang Y., Lai Y., Kweon D.H., Lee N.K., Shin Y.K. Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4087-4092.
9. Choi J.H., Stubblefield B., Cookson M.R., Goldin E., Velayati A., Tayebi N., Sidransky E. Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol. Genet. Metab. 2011, 104:185-188.
10. Cleeter M.W., Chau K.Y., Gluck C., Mehta A., Hughes D.A., Duchen M., Wood N.W., Hardy J., Mark Cooper J., Schapira A.H. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 2013, 62:1-7.
11. Cole N.B., Dieuliis D., Leo P., Mitchell D.C., Nussbaum R.L. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 2008, 314:2076-2089.
12. Colla E., Jensen P.H., Pletnikova O., Troncoso J.C., Glabe C., Lee M.K. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy invivo. J.Neurosci. 2012, 32:3301-3305.
13. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., Liu K., Xu K., Strathearn K.E., Liu F., Cao S., Caldwell K.A., Caldwell G.A., Marsischky G., Kolodner R.D., Labaer J., Rochet J.C., Bonini N.M., Lindquist S. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
14. Crawford G.D., Le W.D., Smith R.G., Xie W.J., Stefani E., Appel S.H. Anovel N18TG29 mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J.Neurosci. 1992, 12:3392-3398.
15. Crivello N.A., Rosenberg I.H., Dallal G.E., Bielinski D., Joseph J.A. Age-related changes in neutral sphingomyelin-specific phospholipase C activity in striatum, hippocampus, and frontal cortex: implication for sensitivity to stress and inflammation. Neurochem. Int. 2005, 47:573-579.
16. Dermentzaki G., Dimitriou E., Xilouri M., Michelakakis H., Stefanis L. Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS One 2013, 8:e60674.
17. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J.Biol. Chem. 2008, 283:9089-9100.
18. Dimant H., Kalia S.K., Kalia L.V., Zhu L.N., Kibuuka L., Ebrahimi-Fakhari D., McFarland N.R., Fan Z., Hyman B.T., McLean P.J. Direct detection of alpha synuclein oligomers invivo. Acta Neuropathol. Commun. 2013, 1:6.
19. Dobrowsky R.T., Kamibayashi C., Mumby M.C., Hannun Y.A. Ceramide activates heterotrimeric protein phosphatase 2A. J.Biol. Chem. 1993, 268:15523-15530.
20. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20:419-425.
21. Ferrer I., Martinez A., Blanco R., Dalfó E., Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J.Neural Transm. 2011, 118:821-839.
22. Foley T.D., Petro L.A., Stredny C.M., Coppa T.M. Oxidative inhibition of protein phosphatase 2A activity: role of catalytic subunit disulfides. Neurochem. Res. 2007, 32:1957-1964.
23. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
24. Gai W.P., Power J.H., Blumbergs P.C., Blessing W.W. Multiple-system atrophy: a new alpha-synuclein disease?. Lancet 1998, 352:547-548.
25. Goker-Alpan O., Stubblefield B.K., Giasson B.I., Sidransky E. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 2010, 120:641-649.
26. Grabowski G.A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008, 372:1263-1271.
27. Hashimoto M., Rockenstein E., Crews L., Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 2003, 4:21-36.
28. Jellinger K.A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol. 2003, 106:191-201.
29. Jellinger K.A. Lewy body-related alpha-synucleinopathy in the aged human brain. J.Neural Transm. 2004, 111:1219-1235.
30. Kragh C.L., Lund L.B., Febbraro F., Hansen H.D., Gai W.P., El-Agnaf O., Richter-Landsberg C., Jensen P.H. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J.Biol. Chem. 2009, 284:10211-10222.
31. Kramer M.L., Schulz-Schaeffer W.J. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J.Neurosci. 2007, 27:1405-1410.
32. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
33. Lee K.W., Chen W., Junn E., Im J.Y., Grosso H., Sonsalla P.K., Feng X., Ray N., Fernandez J.R., Chao Y., Masliah E., Voronkov M., Braithwaite S.P., Stock J.B., Mouradian M.M. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J.Neurosci. 2011, 31:6963-6971.
34. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., Yang H., Uéda K., Chan P., Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454:187-192.
35. Malchiodi-Albedi F., Paradisi S., Matteucci A., Frank C., Diociaiuti M. Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int. J. Alzheimers Dis. 2011, 2011:906964.
36. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
37. Mbefo M.K., Paleologou K.E., Boucharaba A., Oueslati A., Schell H., Fournier M., Olschewski D., Yin G., Zweckstetter M., Masliah E., Kahle P.J., Hirling H., Lashuel H.A. Phosphorylation of synucleins by members of the Polo-like kinase family. J.Biol. Chem. 2010, 285:2807-2822.
38. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
39. Motabar O., Goldin E., Leister W., Liu K., Southall N., Huang W., Marugan J.J., Sidransky E., Zheng W. Ahigh throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Anal. Bioanal. Chem. 2012, 402:731-739.
40. Murphy K.E., Gysbers A.M., Abbott S.K., Tayebi N., Kim W.S., Sidransky E., Cooper A., Garner B., Halliday G.M. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 2014, 137:834-848.
41. Outeiro T.F., Putcha P., Tetzlaff J.E., Spoelgen R., Koker M., Carvalho F., Hyman B.T., McLean P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008, 3:e1867.
42. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
43. Qi Z., Yang W., Liu Y., Cui T., Gao H., Duan C., Lu L., Zhao C., Zhao H., Yang H. Loss of PINK1 function decreases PP2A activity and promotes autophagy in dopaminergic cells and a murine model. Neurochem. Int. 2011, 59:572-581.
44. Roostaee A., Beaudoin S., Staskevicius A., Roucou X. Aggregation and neurotoxicity of recombinant alpha-synuclein aggregates initiated by dimerization. Mol. Neurodegener. 2013, 8:5.
45. Saito Y., Ruberu N.N., Sawabe M., Arai T., Kazama H., Hosoi T., Yamanouchi H., Murayama S. Lewy body-related alpha-synucleinopathy in aging. J.Neuropathol. Exp. Neurol. 2004, 63:742-749.
46. Sasakawa H., Sakata E., Yamaguchi Y., Masuda M., Mori T., Kurimoto E., Iguchi T., Hisanaga S., Iwatsubo T., Hasegawa M., Kato K. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of α-synuclein. Biochem. Biophys. Res. Commun. 2007, 363:795-799.
47. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
48. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Dürr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R., Zabetian C.P., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N.Engl. J. Med. 2009, 361:1651-1661.
49. Sidransky E., Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012, 11:986-998.
50. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
51. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
52. Thayanidhi N., Helm J.R., Nycz D.C., Bentley M., Liang Y., Hay J.C. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 2010, 21:1850-1863.
53. Vernon A.C., Ballard C., Modo M. Neuroimaging for Lewy body disease: is the invivo molecular imaging of alpha-synuclein neuropathology required and feasible?. Brain Res. Rev. 2010, 65:28-55.
54. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
55. Walker D.G., Lue L.F., Adler C.H., Shill H.A., Caviness J.N., Sabbagh M.N., Akiyama H., Serrano G.E., Sue L.I., Beach T.G. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 2013, 240:190-204.
56. Watson R., Blamire A.M., O'Brien J.T. Magnetic resonance imaging in Lewy body dementias. Dement. Geriatr. Cogn. Disord. 2009, 28:493-506.
57. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. Invivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
58. Wu J., Lou H., Alerte T.N., Stachowski E.K., Chen J., Singleton A.B., Hamilton R.L., Perez R.G. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity invitro and invivo. Neuroscience 2012, 207:288-297.
59. Yap T.L., Gruschus J.M., Velayati A., Westbroek W., Goldin E., Moaven N., Sidransky E., Lee J.C. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J.Biol. Chem. 2011, 286:28080-28088.
60. Yu S., Li X., Liu G., Han J., Zhang C., Li Y., Xu S., Liu C., Gao Y., Yang H., Uéda K., Chan P. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007, 145:539-555.
61. Yu S., Zhao T., Guo M., Fang H., Ma J., Ding A., Wang F., Chan P., Fan M. Hypoxic preconditioning up-regulates glucose transport activity and glucose transporter (GLUT1 and GLUT3) gene expression after acute anoxic exposure in the cultured rat hippocampal neurons and astrocytes. Brain Res. 2008, 1211:22-29.
62. Yu S., Zuo X., Li Y., Zhang C., Zhou M., Zhang Y.A., Uéda K., Chan P. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci. Lett. 2004, 367:34-39.
63. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., Del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
64. Zhang Z.X., Roman G.C., Hong Z., Wu C.B., Qu Q.M., Huang J.B., Zhou B., Geng Z.P., Wu J.X., Wen H.B., Zhao H., Zahner G.E. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005, 365:595-597.
65. Zhou J., Broe M., Huang Y., Anderson J.P., Gai W.P., Milward E.A., Porritt M., Howells D., Hughes A.J., Wang X., Halliday G.M. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol. 2011, 121:695-704.